GlassScriptPhysician profile
Paul C Young
NPI 1750318598
$3,746.70
in general payments reported to CMS, 2019-2025
22 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.84 · 2020: $116 · 2021: $303 · 2022: $317 · 2023: $648 · 2024: $928 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,934.78 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $594.34 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $553.70 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $420.62 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $322.03 | 2020-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $314.77 | 2022-2025 | Dyanavel Xr |
| Harmony Biosciences LLC | $279.01 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $194.15 | 2021-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $188.11 | 2020-2023 | Trintellix |
| Axsome Therapeutics, INC. | $165.83 | 2024-2025 | Auvelity |
| Abbvie INC. | $157.98 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $129.64 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $129.04 | 2020-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $51.65 | 2022 | |
| Brainsway USA INC | $49.29 | 2024 | Brainsway Deep Tms System |
| Otsuka America Pharmaceutical, INC. | $48.17 | 2024-2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $38.31 | 2024 | Quviviq |
| Biogen, INC. | $24.36 | 2025 | Zurzuvae |
| Alkermes, INC. | $22.10 | 2025 | Lybalvi |
| Janssen Pharmaceuticals, INC | $18.45 | 2020 | |
| Almatica Pharma LLC | $18.31 | 2025 | Loreev Xr |
| Noven Therapeutics, LLC | $16.00 | 2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.